Latest news! You should not miss

Human papillomavirus vaccine is effective in women with HIV

Papillomavirus - 3d RenderThe women were seropositive for HIV respond well to Gardasil human papillomavirus (HPV) vaccine, offering them protection against cervical cancer, according to a study published inApril 14 electronic edition ofClinical Infectious Diseases. Related recent research has found that both Gardasil and Cervarix are effective in people with HIV. HPV-high risk HPV-more commonly HPV-16 and HPV-18 - can cause cervical, anal, and other types of cancer. Most people are infected with HPV soon after they become sexually active, and the Centers for Disease Control and Prevention (CDC) recommends HPV vaccination for girls age 11-26 and boys age 11-21. Studies have shown that people living with HIV, especially those with compromised immune function, are more likely to be infected with various types of HPV and are less likely to eliminate the virus. Erna Milunka Kojic, Susan Cu-Uvin and colleagues from Brown University conducted a study of women with HIV in the US, Brazil, and South Africa to determine the safety and immunogenicity - or the ability to stimulate an immune response - of the Gardasil vaccine. HPV quadrivalent designed to protect against HPV types 6, 11, 16 and 18 (types 6 and 11 cause genital warts). The Group AIDS Clinical Trials investigated 5240 individuals, which included 319 HIV-positive women who were stratified by age 13-45 and T-CD4 cell counts. > 350 cells / mm3, 200-350 cells / mm3Or<200 cells/ Mm3. Most (56%) were black, 31% were Hispanics or Latinos, 11% were white and the average age was 36 years. The median CD4 count was 310 cells / mm3- Indicating the need for anti-retroviral therapy (ART) - but only 40% had detectable HIV viral load.   Results
  • At baseline, 4% of the participants were infected with 4 all HPV types covered by the vaccine.
  • In 28 weeks after immunization, seroconversion rates - or the development of protective antibodies against HPV types 6, 11, 16 and 18, among women not already infected with the virus of each type were:
The> 350 cells / mm3:96%, 98%, 99%, and 91%, respectively. The 200-350 cells / mm3: 100%, 98%, 98%, and 85%, respectively. O <200 cells / mm3:84% 92% 93% and 75%, respectively.
  • At all levels of CD4 cells, the response was better for HPV types 6, 11 and 16 compared with 18 type.
  • And lower cell count CD4 high viral load (> 10.000 copies / mL) was also associated with a poor response to the vaccine.
  • The vaccine was generally well tolerated and no safety issues were identified.
"A quadrivalent HPV vaccine targeting 6, 11, 16 and 18 has been safe and immunogenic in HIV-infected women for 13-45 for years," the study authors concluded. "Women with HIV viral load> 10.000 copies / mL and / or counts of CD4 <200 cells / mm 3, had lower seroconversion." The fact that only 4% of HIV-positive women in the present study had all of the 4 types of HPV covered by the vaccine indicate that the remainder should benefit from the same, since many were above the age cut of 26 years, as the CDC guidelines. These data support the World Health Organization's recommendation that women with HIV should be vaccinated against HPV. Gardasil vs Cervarix In one study described inApril 15Journal of Infectious Diseases, Lars Toft of Aarhus University Hospital in Denmark and colleagues compared the immunogenicity of Gardasil, Cervarix in people with HIV. While Gardasil protects against 4 types of HPV, Cervarix is ​​a bivalent vaccine designed only to prevent cancer - making immunogenicity with the 16 and 18 types. This double-blind randomized trial included 92 HIV-positive women and men who were randomly assigned to receive 3 doses of Gardasil, Cervarix, at baseline and at 1,5 and 6 months later. Immunogenicity was assessed for a maximum period of 12 months. The researchers did not observe differences in antibody levels against HPV-16 in participants who received Gardasil or Cervarix. However, antibodies against HPV-18 were higher in the Gardasil group. Among people receiving Cervarix, women achieved high antibody titers against HPV-16 and HPV-18 than in men; there were no gender differences seen among recipients of Gardasil. Mild reaction at the injection site were more common in the Cervarix group (91% vs 70%), but there were no serious adverse effects in either arm. "Both vaccines were immunogenic and well tolerated," the authors concluded. "In comparison to Gardasil, Cervarix vaccine produces superior induced response among HIV-infected women, considering that in HIV-infected men the difference in immunogenicity was less marked."uman Papillomavirus Vaccine Is Effective for Women with HIVReviewed by Mara Macedo References IN Kojic, M Kang, MS Céspedes, Cu-Uvin S, et al. Safety and immunogenicity of tetravalent vaccine against human papillomavirus vaccine in HIV-infected women 1 patients.Clinical picture Infectious Diseases. 14 2014 OF APRIL (Epub). L Toft, M Storgaard, M Müller, et al. Fellow immunogenicity and reatogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial.Journal of Infectious Diseases209 (8): 1165-1173. 15 2014 OF APRIL. Another source Brown University. HIV + women respond well to the HPV vaccine.Press release16 de Abril OF 2014.
About Claudio Souza do Soropositivo.Org (506 articles)
Yes, this is the photo of me! My niece asked me to put this picture on my profile! .... I had here a description of me that one person described as "irreverent". This is really a euphemistic way of classifying what was here. All I know is that an "NGO" which occupies a building of 10 floors has established a partnership with me, and I have the logs of the partnership time, which was more a vampirism because for each 150 people leaving my site, clicking on them, there was, on average, one that came in. WHEN I ENTERED AND ENTERED
Whatsapp WhatsApp Us
%d Bloggers like this: